Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric‐like GIMEMA LAL ‐1308 trial

2020 ◽  
Author(s):  
Anna Maria Testi ◽  
Martina Canichella ◽  
Antonella Vitale ◽  
Alfonso Piciocchi ◽  
Anna Guarini ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Young Adult ◽  
Phase Ii ◽  
Lymphoblastic Leukemia ◽  
Adolescent And Young Adult ◽  
Adult Acute Lymphoblastic Leukemia

A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia

2000 ◽  
Vol 24 (3) ◽  
pp. 183-187 ◽  
Author(s):  
Peter J. Rosen ◽  
Cathryn Rankin ◽  
David R. Head ◽  
David H. Boldt ◽  
Frederick W. Luthardt ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Lymphoblastic Leukemia ◽  
High Dose ◽  
Adult Acute Lymphoblastic Leukemia

scholarly journals How I Treat Adult Acute Lymphoblastic Leukemia in India

2021 ◽  
Author(s):  
Prasanth Ganesan ◽  
Smita Kayal
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Adult Population ◽  
Current Approach ◽  
Adolescent And Young Adult ◽  
Infection Rates ◽  
Treatment Regimens ◽  
High Infection ◽  
Adult Acute Lymphoblastic Leukemia ◽  
Young Adult Population

AbstractSurvival of children with acute lymphoblastic leukemia (ALL) has improved from 10% to 90% over the last six decades. Survival gains in adult ALL have been more modest and confined to the adolescent and young adult population. Age is an important factor in determining outcomes in ALL. Additional factors like adverse biology, less intense treatment regimens, and poorer tolerance to therapy contribute to inferior survival among adults. Indian physicians face unique challenges while managing these patients. These are high infection rates, limited access to high-end investigations, and newer drugs. In this context, the management decisions in an individual patient are highly nuanced. Through a case-based review, we discuss representative scenarios in adult ALL where we detail our current approach to treatment in the context of available evidence.

Sign in / Sign up

Export Citation Format

Share Document